Synthesis and Antiobesity Properties of 6-(4-Chlorophenyl)-3-(4-((3,3-difluoro-1-hydroxycyclobutyl)methoxy)-3-methoxyphenyl)thieno[3,2-d]pyrimidin-4(3H)-one (BMS-814580): A Highly Efficacious Melanin Concentrating Hormone Receptor 1 (MCHR1) Inhibitor.

The potent MCHR1 in vitro and in vivo antagonist activity of a series of cyclic tertiary alcohols derived from compound 2b is described. Subsequent pharmacokinetic and pharmacodynamic studies identified BMS-814580 (compound 10) as a highly efficacious antiobesity agent with a relatively clean in vitro and in vivo safety profile.

[1]  P. Gennemark,et al.  Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties. , 2016, Journal of medicinal chemistry.

[2]  A. Johansson,et al.  Novel MCH1 receptor antagonists: a patent review , 2015, Expert opinion on therapeutic patents.

[3]  A. Halpern,et al.  Why are anti-obesity drugs stigmatized? , 2015, Expert opinion on drug safety.

[4]  J. Barrish,et al.  Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate. , 2014, Journal of medicinal chemistry.

[5]  T. Kitka,et al.  Recent patents on novel MCH1 receptor antagonists as potential anti-obesity drugs. , 2014, Recent patents on CNS drug discovery.

[6]  J. Jaén,et al.  Evaluation of AMG 076, a potent and selective MCHR1 antagonist, in rodent and primate obesity models , 2013, Pharmacology research & perspectives.

[7]  M. Pelleymounter,et al.  Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet‐Induced Obese (DIO) Rats , 2012, Obesity.

[8]  M. Lindstrom,et al.  Discovery of a novel melanin concentrating hormone receptor 1 (MCHR1) antagonist with reduced hERG inhibition. , 2012, Bioorganic & medicinal chemistry letters.

[9]  Anders Johansson,et al.  Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists , 2011, Expert opinion on therapeutic patents.

[10]  C. Maggi,et al.  Modulation on C‐ and N‐Terminal Moieties of a Series of Potent and Selective Linear Tachykinin NK2 Receptor Antagonists , 2010, ChemMedChem.

[11]  Xia Li,et al.  Preclinical Evaluation of Melanin-Concentrating Hormone Receptor 1 Antagonism for the Treatment of Obesity and Depression , 2009, Journal of Pharmacology and Experimental Therapeutics.

[12]  A. Souers,et al.  Lead optimization of melanin concentrating hormone receptor 1 antagonists with low hERG channel activity. , 2008, Current topics in medicinal chemistry.

[13]  A. Vasudevan,et al.  Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. , 2007, Current topics in medicinal chemistry.

[14]  D. Luthin.  Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists , 2007 .

[15]  E. Carreira,et al.  Oxetanes as promising modules in drug discovery. , 2006, Angewandte Chemie.

[16]  M. J. Bishop,et al.  The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[17]  G. Kennett,et al.  The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake , 2006, Pharmacology Biochemistry and Behavior.

[18]  E. Maratos-Flier,et al.  Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. , 2006, Endocrine reviews.

[19]  M. Fray,et al.  A Practical Synthesis of 3,3‐Difluorocyclobutane Carboxylic Acid , 2005 .

[20]  H. Hsiung,et al.  Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. , 2002, Endocrinology.

[21]  B. Lowell,et al.  Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. , 2001, The Journal of clinical investigation.

[22]  B. Lowell,et al.  Mice lacking melanin-concentrating hormone are hypophagic and lean , 1998, Nature.

[23]  D. M. Al-Fekri,et al.  3,3-Difluorocyclobutene. Synthesis and reaction with diazomethane , 1987 .

[24]  K. Tamao,et al.  Silafunctional compounds in organic synthesis. 27. (Isopropoxydimethylsilyl)methyl grignard reagent: A new nucleophilic hydroxymethylating agent for aldehydes and ketones , 1985 .

[25]  W. Doering,et al.  1,2-Dimethylenecyclobutane rearrangement , 1967 .

[26]  John D. Roberts,et al.  Small-ring Compounds. XX. 1,3-Dimethylenecyclobutane and Related Compounds , 1958 .

[27]  John D. Roberts,et al.  Small-Ring Compounds. XV. Methylenecyclobutene and Related Substances , 1956 .

[28]  T. Miyoshi,et al.  Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight , 1997 .

[29]  Printed in U.S.A. Copyright © 2001 by The Endocrine Society Melanin-Concentrating Hormone Receptor Is a Target of Leptin Action in the Mouse Brain , 2022 .